pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›DURAVYU
drug
save

vorolanib

Phase 3updated 3mo ago
by $EYPT EyePoint, Inc.
Phase 3
community read0 votes

indications

indications
Diabetic Macular Edema

all catalysts(0)

nothing on the calendar yet

Trials studying vorolanib

  • phase2Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancerterminatedn=11
  • phase2Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumorscompletedn=88

News(5)

  • STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
    Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal
    stat · 2d ago
  • STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
    Eyepoint said patients given its experimental treatment for wet AMD failed to maintain vision with less frequent injections compared to a standard treatment.
    stat · 3d ago
  • EyePoint plummets on pivotal data for main drug
    Though its drug missed the key goal of a wet AMD study, EyePoint — as well as analysts — see a path toward approval. Investors may be harder to win over, however.
    biopharma_dive · 3d ago
  • EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
    EyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.
    biospace · 3d ago
  • Chutes & Ladders—Cue lines up new CMO and research head
    Cue Biopharma is tapping in a new chief medical officer and head of R&D in Dominic Borie, M.D., Ph.D., a physician-scientist with over two decades of industry experience.
    fiercebiotech · 1mo ago
brand
DURAVYU
generic
vorolanib [INN]
indication
Wet (Neovascular / Exudative) Macular Degeneration
phase
phase_3
Data sources
ClinicalTrials.gov
last refreshed 39m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?